1 Title

- 2 Risk of Adverse Events Following Monovalent Third or Booster Dose of COVID-19 mRNA
- 3 Vaccination in U.S. Adults Ages 18 Years and Older
- 4 Azadeh Shoaibi, PhD, MHS,¹* Kathryn Matuska, BA,²* Patricia C. Lloyd, PhD, ScM,¹ Hui Lee
- 5 Wong, PhD,¹ Joann F. Gruber, PhD,¹ Tainya C. Clarke, PhD,¹ Sylvia Cho, PhD,¹ Emily
- 6 Lassman, MS,² Hai Lyu, MS,² Rowan McEvoy, BS,² Zhiruo Wan, MSE,² Mao Hu, BS,² Sandia
- 7 Akhtar, BS,² Yixin Jiao, MPP,² Yoganand Chillarige, MPA,² Daniel Beachler, PhD,³ Alex
- 8 Secora, PhD,⁴ Nandini Selvam, PhD, MPH,⁴ Djeneba Audrey Djibo, PhD, MSBME,⁵ Cheryl N
- 9 McMahill Walraven, MSW, PhD,⁵ John D. Seeger, DrPH, PharmD,⁶ Kandace L. Amend, PhD,⁶
- 10 Jennifer Song, MA, MURP,⁶ Robin Clifford, MS, BS,⁶ Jeffrey A. Kelman, PhD,⁷ Richard A.
- 11 Forshee, PhD,¹ Steven A. Anderson, PhD¹

12 Authors

- 13 ¹US Food and Drug Administration, Silver Spring, MD, USA
- ¹⁴ ²Acumen LLC, Burlingame, CA, USA
- 15 ³Carelon Research, Wilmington, DE, USA
- 16 ⁴IQVIA, Falls Church, VA, USA
- 17 ⁵CVS Health/Aetna, Blue Bell, Pennsylvania, USA
- 18 ⁶Optum Epidemiology, Boston, MA, USA
- 19 ⁷Centers for Medicare & Medicaid Services, Washington, DC, USA
- 20
- 21 *First Authors

22 Corresponding Author

- 23 Patricia C. Lloyd, PhD, ScM
- 24 Office of Biostatistics and Pharmacovigilance
- 25 Center for Biologics Evaluation and Research
- 26 U.S. Food & Drug Administration
- 27 10903 New Hampshire Ave., Building 71
- 28 Silver Spring, MD 20993
- 29
- 30 Email: <u>patricia.lloyd@fda.hhs.gov</u>
- 31
- 32 Manuscript Word Count
- 33 2,960/3,000 words

34 Abstract (248 words)

35 Background

- 36 The U.S. FDA authorized the monovalent third primary series or booster doses of COVID-19
- 37 mRNA vaccines in August 2021 for persons 18 years and older. Monitoring of outcomes
- 38 following updated authorizations is critical to evaluate vaccine safety and can provide early
- 39 detection of rare adverse events (AEs) not identified in pre-licensure trials.

40 Methods

- 41 We evaluated the risk of 17 AEs following third doses of COVID-19 mRNA vaccines from
- 42 August 2021 through early 2022 among adults aged 18-64 years in three commercial databases
- 43 (Optum, Carelon Research, CVS Health) and adults aged >65 years in Medicare Fee-For-
- 44 Service. We compared observed AE incidence rates to historical (expected) rates prior to the
- 45 pandemic, estimated incidence rate ratios (IRRs) for the Medicare database and pooled IRR
- 46 across the three commercial databases. Analyses were also stratified by prior history of COVID-
- 47 19 diagnosis. Estimates exceeding a pre-defined threshold were considered statistical signals.

48 **Results**

- 49 Four AEs met the threshold for statistical signals for BNT162b2 and mRNA-1273 vaccines
- 50 including Bell's Palsy and pulmonary embolism in Medicare, and anaphylaxis and
- 51 myocarditis/pericarditis in commercial databases. Nine AEs and three AEs signaled among
- 52 adults with and without prior COVID-19 diagnosis, respectively.
- 53

54 Conclusions

- 55 This early monitoring study identified statistical signals for AEs following third doses of
- 56 COVID-19 mRNA vaccination. Since this method is intended for screening purposes and
- 57 generates crude results, results do not establish a causal association between the vaccines and
- 58 AEs. FDA's public health assessment remains consistent that the benefits of COVID-19
- 59 vaccination outweigh the risks of vaccination.

60 Keywords

61 COVID-19 mRNA vaccines, monovalent booster, Pfizer-BioNTech, Moderna, Medicare,
 62 COVID-19 vaccine safety

63 Introduction

64 In the United States (U.S.), the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)

65 mRNA vaccines are available to prevent severe Coronavirus disease 2019 (COVID-19).^{1,2} For

66 monovalent formulations, third doses as primary series doses were recommended for persons

67 with immunocompromising conditions as of August 12, 2021, and a first booster dose (outside of

the primary series) was authorized through Emergency Use Authorization (EUA) by the U.S.

69 Food and Drug Administration (FDA) for everyone aged 18 years and older from November 19,

70 2021 to April 18, 2023. Statistical signals have been observed in active surveillance of the

71 monovalent mRNA vaccines.³⁻⁵ Thus, the FDA Biologics Effectiveness and Safety (BEST)

72 Initiative, an active surveillance program for post-market surveillance of biologic products,

73 conducted this study to investigate the safety of COVID-19 mRNA vaccines among individuals

aged 18 to 64 years in the commercially insured population and individuals aged 65 years and

75 older in the Medicare population by evaluating the rates of 17 adverse events (AEs) of interest

76 following third doses by comparing them to historical control (expected) rates for their

respective AEs. Results from this signal detection study do not establish a causal association

78 between the vaccines and AEs.

79 Methods

80 Data Sources

81 This study used administrative claims data from the Centers for Medicare & Medicaid Services
82 (CMS) Medicare (Fee-For-Service) database and from three commercial health insurance

83	databases: CVS Health, Optum pre-adjudicated claims, and Carelon Research (Supplemental
84	Table 1). The commercial data sources were supplemented with Immunization Information
85	System (IIS) data from local and state jurisdictions to increase the capture of vaccinations. ⁶

86 Study Population and Period

87 The study population included a commercially insured population (aged 18-64 years) and the 88 publicly insured Medicare Fee-For-Service population (aged 65 years and older) who received a 89 COVID-19 mRNA third dose vaccination from the study start date of August 12, 2021, when the 90 FDA authorized an additional vaccine dose for certain immunocompromised individuals,⁷ 91 through database-specific study end dates. Data are included through April 2022 for Optum and 92 Carelon, February 2022 for CVS Health, and March 2022 for Medicare enrollees. For inclusion 93 in AE-specific analyses, persons must have been continuously enrolled in a medical health 94 insurance plan from the start of the AE-specific clean window through the date of their third 95 COVID-19 vaccine dose. This AE-specific pre-vaccination clean window was defined as a 96 specific number of days before vaccination date when a patient must not have had the AE (Table 97 1).

98 Exposure and Follow-Up

99 Exposure was defined as the receipt of a third dose of the BNT162b2 COVID-19 or the mRNA-

100 1273 COVID-19 vaccine (Supplemental Table 2). Vaccinations were identified using brand and

101 dose-specific Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding

102 System (HCPCS) codes or National Drug Codes (NDCs) in the professional, outpatient

103 institutional, inpatient, or prescription drug care settings,⁸ and were identified by CVX (vaccine

104 administered) product codes in IIS data sources.

Dose assignment was based on the chronological order in which vaccinations were observed for each person. Third doses were restricted to doses following a two-dose primary series of mRNA vaccines. If a patient was administered more than 3 doses of BNT162b2 or mRNA-1273 vaccine, follow-up time was censored at the time of the fourth dose administration.

- 109 Patients who received heterologous vaccine brands for the primary series and third dose and
- 110 persons who received the first booster dose of Ad26.COV2.S (Janssen) vaccine were included in
- 111 the descriptive analyses but not in the inferential analyses due to small sample size. First booster

112 doses of the Ad26.COV2.S vaccine were restricted to doses following a one-dose primary series,

- and follow-up time was censored at the time of administration if a patient was administered more
- 114 than 2 doses of Ad26.COV2.S.
- 115 Follow-up time began on the day after vaccination and was censored at death, disenrollment, end
- 116 of AE-specific risk window (Table 1), end of study period, a subsequent COVID-19 vaccine
- 117 dose, or at AE occurrence, whichever came first.

118 Adverse Events of Interest

119 Claims-based AE algorithms, pre-vaccination clean windows, and post-vaccination risk windows

120 were selected based on literature review and clinical consultation. All AEs (Table 1) were

121 identified using International Classification of Diseases, Tenth Revision, Clinical Modification

- 122 (ICD-10-CM) diagnosis codes.⁸ Claims from inpatient facilities (IP), emergency department
- 123 encounters in outpatient facilities (OP-ED), and all outpatient facilities and individual providers
- 124 or professionals (OP/PB) were used to identify AEs.

125 Statistical Analyses

126 The vaccine dose count was summarized by brand for each AE (Table 2). The count and 127 proportion of heterologous vaccine brand administration of third doses was also summarized. 128 This study was designed as a retrospective cohort analysis with a historical comparator group. 129 The primary analysis compared the observed rate of the AE of interest in the post-vaccination 130 risk window to the rate in a database-specific historical control population, and incidence rate 131 ratios (IRR) were estimated. The observed rate of each AE was adjusted based on observation 132 delay for that outcome in 2019 using a similar approach as described in the literature for partially accrued data.⁹ We calculated database-specific comparator rates as the annual AE rates within 133 134 the overall and influenza-vaccinated populations in the pre-COVID-19 (2017-2019) and during-135 COVID-19 pandemic (June 2020-December 10, 2020) periods. The comparator rate used for the 136 analysis was selected to enhance the sensitivity of the test for signal detection. If annual rates in 137 the historical period differed, as assessed by comparing the 95% confidence intervals (CI), we 138 selected the lowest rate; otherwise, the median annual rate was selected. Pre-COVID-19 rates 139 from 2019 were selected for most outcomes; however, when the during-COVID-19 rate (June-140 December 10, 2020) did not return to pre-COVID-19 levels, rates from 2020 were selected.⁸ 141 There were no adjustments for baseline clinical characteristics. Comparator rates were generated 142 stratified by age and sex when sufficient counts in the respective strata were available in all 143 databases. Also, comparator rates were generated by nursing home residency status and race in 144 the Medicare population only.

Analyses for myocarditis/pericarditis were stratified by care setting (all settings and IP/OP-ED settings) and age (18-45 years and 46-64 years) in the commercially insured population to more granularly assess risk based on prior evidence regarding increased risk of

6

myocarditis/pericarditis following COVID-19 mRNA vaccination particularly amongst younger
 males.¹⁰⁻²²

150 For each potential AE, Poisson models were used to estimate the incidence rate (IR) per 100,000 151 person-years with 95% CI and the IRR of observed IR vs. expected IR with 95% CI. One-sided 152 tests were conducted with an overall alpha of 2.5% and with testing margins selected for each 153 AE based on clinical significance and expert guidance to avoid detection of false-positive results 154 and characterization of non-clinically meaningful, minimal risk increases. In the commercially 155 insured population, the null hypotheses were IRR = 1.5 for anaphylaxis, transverse myelitis, and 156 myocarditis/pericarditis; 2.5 for encephalitis or encephalomyelitis, narcolepsy, and Guillain-157 Barré syndrome (GBS); and 1.25 for all other outcomes. To detect any increase in risk in the 158 Medicare population, in which outcomes are more common, more sensitive tests were conducted 159 where the null hypothesis was IRR = 1 for all AEs. A statistical signal occurred if the observed 160 IRR exceeded the null hypothesis and the null hypothesis was not within the IRR 95% CI which 161 was used as a threshold for determining whether the result was likely to occur due to chance. 162 Statistical testing was only conducted for individuals who received the same vaccine brand for 163 primary series and third doses.

To account for prior COVID-19 infection as a potential confounder, we conducted a secondary
analysis for each AE stratified by history of COVID-19 diagnosis identified by diagnosis of
COVID-19 in any care setting (identified by U07.1 ICD-10-CM code) on or following April 1,
2020.

- 168 IRs and IRRs were generated for the Medicare database separately and pooled across the three
- 169 commercial databases using meta-analysis with a random-effects and fixed-effects models.
- 170 Between-study heterogeneity was assessed using a I^2 statistic.²³

171 **Results**

172 Descriptive Analyses

- 173 Across the commercial insurance databases, 3,803,442 beneficiaries received BNT162b2 and
- 174 2,400,502 beneficiaries received mRNA-1273 third dose vaccines. The count of vaccine doses
- 175 was summarized by brand for each AE for all COVID-19 vaccines (Table 2) and AE-specific
- analyses (Supplemental Table 3). A large proportion of third doses was mRNA vaccines; we did
- 177 not conduct inferential analyses on the Ad26.COV2.S vaccine due to the small number of doses
- administered. Approximately 64% 83% of vaccinations across brands in commercial databases
- 179 were eligible for the analysis and contributed to an AE-specific cohort. In the Medicare database,
- 180 3,336,862 beneficiaries received BNT162b2 and 3,399,048 beneficiaries received mRNA-1273
- 181 third dose vaccines; more than 90% of these vaccinations across brands were eligible for the
- analysis and contributed to an AE-specific cohort (Supplemental Table 3). Less than 13% of
- 183 cases with an observed AE across databases had an associated prior COVID-19 diagnosis
- 184 (Supplemental Table 4, Supplemental Table 5). Most people received the same vaccine brand for
- 185 primary series and third doses (Supplemental Table 6).

186 Results of Primary and Secondary Analyses – Persons 18 to 64 years

- 187 Among the 17 AEs of interest evaluated in the commercially insured population, two AEs met
- 188 the threshold for a statistical signal in primary analyses. A signal was observed post-BNT162b2
- third dose vaccination for anaphylaxis (IRR = 4.92, 95% CI = 2.20-10.98). Following mRNA-

1273 third dose vaccination, signals were observed for anaphylaxis (IRR = 5.70, 95% CI = 1.69–
19.21) and myocarditis/pericarditis: IP/OP-ED (18-45 years) (IRR = 3.38, 95% CI = 1.51–7.58)
192 (Table 3).

- 193 In the secondary analyses stratified by prior COVID-19 diagnosis, statistical signals were
- 194 observed in the population with a prior COVID-19 diagnosis following BNT162b2 third dose
- vaccination for anaphylaxis (IRR= 37.26, 95% CI = 6.69–207.58); encephalitis or
- encephalomyelitis (IRR= 26.85, 95% CI = 7.43 96.99); and unusual site TTS (IRR= 8.43, 95%
- 197 CI = 1.51-46.96) (Supplemental Table 4). The following statistical signals were observed
- 198 following mRNA-1273 third dose vaccination: myocarditis/pericarditis, all settings for 18-45
- 199 years (IRR= 7.22, 95% CI = 2.58–20.19) and 46-64 years (IRR= 6.61, 95% CI = 3.26–13.41);
- 200 myocarditis/pericarditis, IP/OP-ED settings for 46-64 years (IRR= 11.35, 95% CI = 4.06-31.74);
- 201 common site thrombosis with thrombocytopenia (TTS) (IRR= 5.83, 95% CI = 2.28-14.92); and
- 202 GBS (IRR= 18.19, 95% CI = 3.26–101.35).
- 203 In the population without a prior history of COVID-19 diagnosis, a signal was observed post-
- BNT162b2 third dose vaccination for anaphylaxis (IRR= 6.21, 95% CI = 2.50–15.39). In
- addition, signals were observed post-mRNA-1273 third dose vaccinations for
- 206 myocarditis/pericarditis, IP/OP-ED settings for 18-45 years (IRR= 3.63, 95% CI = 1.62–8.15);
- and anaphylaxis (IRR= 6.15, 95% CI = 1.82-20.71) (Supplemental Table 4).

208 Results of Primary and Secondary Analyses –Persons 65 years and older

- 209 Statistical signals were observed for two AEs in the primary analysis in the Medicare population
- 210 following third dose vaccinations. Statistical signals were identified following BNT162b2 third
- dose vaccinations for Bell's Palsy (BP) (IRR = 1.11, 95% CI = 1.03 1.19) and pulmonary

embolism (PE) (IRR = 1.05, 95% CI = 1.001 - 1.100) (Table 4). No signals were identified

- 213 following mRNA-1273 third dose vaccinations (Table 4).
- In the secondary analyses stratified by prior COVID-19 diagnosis, five AEs met the threshold for
- a statistical signal. In the population with a prior COVID-19 diagnosis, signals were observed for
- 216 PE following BNT162b2 (IRR = 1.36, 95% CI = 1.17–1.58) and mRNA-1273 third dose
- 217 vaccinations (IRR = 1.43, 95% CI = 1.20–1.69); acute myocardial infarction (AMI) following
- 218 BNT162b2 (IRR = 1.15, 95% CI = 1.02-1.29) and mRNA-1273 third dose vaccinations (IRR =
- 219 1.33, 95% CI = 1.16–1.52). In addition, following BNT162b2 third dose vaccination, signals
- 220 were observed for immune thrombocytopenia (ITP) (IRR = 1.66, 95% CI = 1.17-2.29) and
- 221 myocarditis/pericarditis (IRR = 1.89, 95% CI = 1.18–2.86).
- 222 In the population without a prior history of COVID-19 diagnosis, a signal was observed for BP
- (IRR = 1.11, 95% CI = 1.03-1.19) following BNT162b2 third dose vaccination (Supplemental
- Table 6). While more AEs of interest with elevated risk were observed in the secondary analysis
- compared to the primary analysis, smaller sample sizes reflected wider 95% CI estimates
- 226 (Supplemental Tables 4-5).

227 **Discussion**

- In this large population-based study we investigated the safety of third doses of COVID-19
- 229 mRNA vaccines by examining the risk of 17 AEs following vaccination in a signal detection
- study as the first step in the safety surveillance process.
- 231 The primary analyses of the study found statistical signals for four AEs. Myocarditis/pericarditis
- and anaphylaxis have been reported to be associated with the primary doses of vaccines.^{3,4,8,10-}
- ^{22,24} There is a high level of outcome misclassification (a non-case being identified as a case or

234	vice versa) associated with the detection of BP cases and hence uncertainty with its signal as
235	results from a medical record review (MRR) of a sample of BP cases in our other COVID-19
236	vaccine studies showed a low positive predictive value (PPV) (<20%, data not shown) of the
237	claims-based diagnosis codes used to identify cases indicating that most cases resulting in the
238	signal were not true cases. The PE signal was marginal and similar to inconsistent results
239	detected in previous COVID-19 vaccine safety studies where a protective effect following third
240	doses of both mRNA brands and a small statistically significant elevated risk following
241	BNT162b2 primary series were observed for PE. ²⁴
242	Among those with a prior COVID-19 diagnosis, nine AEs signaled. Most of these AEs have
243	been reported to be associated with COVID-19 infection itself. ²⁵⁻²⁷ In adults aged 18-64 years, all
244	signals in populations with and without prior COVID-19 diagnosis arose from a small number of
245	cases. Similar to BP, our MRR of ITP cases in other COVID-19 vaccines safety studies
246	suggested a low PPV (<10%, data not shown) of the claims-based diagnosis codes used to
247	identify cases indicating that most cases identified for inclusion were not true cases. Moreover,
248	given the small number of cases, wide 95% CIs, and IRRs that are unadjusted for confounders,
249	these signals carry a high level of uncertainty and should be interpreted cautiously.
250	In the population without a prior COVID-19 diagnosis, three AEs signaled. The BP signal may
251	be explained by potential outcome misclassification, and the anaphylaxis and
252	myocarditis/pericarditis signals are consistent with the current literature. ^{3,10-15}
253	This study has several strengths. The study included a large U.S. adult population covered by
254	commercial insurance or Fee-For-Service Medicare. Because of the large sample size, the study
255	had higher power to detect a smaller increase in risk of rare AEs after vaccination that may not

256 be captured in pre-authorization clinical trials. Linkage of the commercial administrative claims 257 databases to the IIS databases captured more COVID-19 vaccines administered. The 258 retrospective cohort design with the use of historical comparator group allowed a rapid safety 259 evaluation of vaccines as the first step in the active surveillance process. 260 There are several limitations in this study. Aggregate historical rates rather than individuals were 261 used as the comparator which increases the potential for confounding and bias. Thus, the study 262 results are crude or unadjusted for confounders, and do not establish a causal relationship 263 between the vaccines and AEs. The stratified results should also be interpreted in the context of 264 uncertainty and with caution. Although this study design was unable to disentangle the effect of 265 prior COVID-19 infection and COVID-19 vaccines on the rates of AEs, several AEs which signaled in the population with a prior history of COVID-19 diagnosis are known to be 266 associated with COVID-19 infection.²⁵⁻²⁷ Therefore, it is likely that a number of detected signals 267 268 from these crude results may be associated with the prior history of COVID-19 diagnosis. 269 In this study, AEs were identified by diagnosis codes in claims databases which are subject to 270 coding errors, and the study did not conduct MRR for all AEs to verify the true cases. Thus, 271 outcome misclassification cannot be ruled out and could also bias results. The misclassification 272 also applies to detection of prior COVID-19 infection in claims databases for the same reason as 273 well as others such as use of home tests or not seeking medical care for the infection. Several 274 identified signals arose from a very small number of AE cases. AE risk intervals were pre-275 specified based on literature review and clinical input, but their misspecification could lead to 276 bias. The large sample size, inclusion of many AEs, and the number of statistical tests could 277 increase the probability of false-positive results. Additionally, our study may not have captured 278 all COVID-19 vaccines administered as some people may have received vaccines from sources

that did not submit claims to insurance carriers, such as mass vaccination sites. Lastly, the results of this study may not be generalizable to the portion of the U.S. population who is uninsured or carries other types of health insurance.

282 Since the authorization or approval of the mRNA vaccines that were evaluated in this study,

there have been additional FDA authorizations of COVID-19 vaccines. This study did not

include second booster doses authorized for those 50 years and older or those 12 years and older

with certain immunocompromised conditions (authorized March 29, 2022), third doses for

children ages 5 to 11 years (authorized May 17, 2022), or bivalent booster doses for individuals

287 12 years and older (authorized August 31, 2022) as these vaccines were not yet authorized for

use at the time this study was conducted.^{1,28-30} Active safety surveillance is ongoing to expand

the monitoring of AEs to include individuals who receive these vaccinations.

290 In conclusion, this signal detection study detected multiple signals after exposure to the third

291 dose of COVID-19 mRNA vaccines. The results of this study must be interpreted in the context

of the study design, statistical methods, and their limitations; thus, some of the safety signals

293 detected may be false positive results. While this study has major limitations, it contributes to the

signal detection phase in the multi-step surveillance process for COVID-19 mRNA vaccines.

FDA's public health assessment remains consistent that the benefits of COVID-19 vaccination

296 outweigh the risks of COVID-19 disease, and safety surveillance of new COVID-19 vaccines is

ongoing.

Tables

Table 1. Study Specifications: Adverse Events (AEs), Care Settings, Clean Windows, and Risk Windows for the Medicare and Commercial Databases

Adverse Events	Care Setting	Clean Window	Risk Window
Acute Myocardial Infarction	IP	365 days	$1-28 \text{ days}^{31,32}$
Anaphylaxis	IP, OP-ED	30 days	0-1 days ^{33,34}
Appendicitis	IP, OP-ED	365 days	1-42 days ^{35,36}
Bell's Palsy	IP, OP/PB	183 days	1-42 days ³⁷
Common Site Thrombosis with Thrombocytopenia Syndrome†	IP, OP/PB	365 days	1-28 days ³⁸
Deep vein thrombosis	IP, OP/PB	365 days	1-28 days ^{39,40}
Disseminated Intravascular Coagulation	IP, OP-ED	365 days	$1-28 \text{ days}^{41}$
Encephalitis or Encephalomyelitis	IP	183 days	$1-42 \text{ days}^{42}$
Guillain-Barré Syndrome	IP- primary position only	365 days	1-42 days ^{43,44}
Hemorrhagic Stroke	IP	365 days	1-28 days ^{31,32}
Immune Thrombocytopenia	IP, OP/PB	365 days	1-42 days ^{45,46}
Mara and dia (Dani and dia	IP, OP/PB	365 days	1-21 days ⁴⁷
Myocarditis/Pericarditis	IP, OP-ED**	365 days	1-21 days ⁴⁷
Narcolepsy	IP, OP/PB	365 days	1-42 days ⁴⁸⁻⁵⁰
Non-hemorrhagic Stroke	IP	365 days	1-28 days ^{31,32}
Pulmonary Embolism	IP, OP/PB	365 days	1-28 days ^{39,40}
Transverse Myelitis	IP, OP-ED	365 days	1-42 days ⁵¹
Unusual Site Thrombosis with Thrombocytopenia Syndrome †	IP, OP-ED	365 days	1-28 days ⁵²

Definitions: Clean window was an interval used to define incident outcomes where an individual entered the study cohort only if the AE did not occur during that interval. The anchor date of the clean window was the date of third or booster dose vaccination. Risk window was an interval during which occurrence of the AE would be included in the analyses. All risk windows were selected based on input from clinicians and observations from the primary series analyses.

Care Settings Definition: IP referred to inpatient facility claims. OP-ED referred to a subset of outpatient facility claims occurring in the emergency department. OP/PB referred to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service.

**Only included in the commercial claims analyses

†Both common site thrombosis with thrombocytopenia syndrome and unusual site thrombosis with thrombocytopenia syndrome were composite outcomes consisting of a thrombotic event (composed of other events such as acute myocardial infarction, deep vein thrombosis etc.,) and a thrombocytopenia event (defined in the IP, OP/PB setting). The overall setting definition for each outcome depended on individual setting definitions for each of these components.

Table 2. Number of Third COVID-19 Vaccine Doses Administered Stratified by AdverseEvent and Vaccine Brand

Adverse Event	Vaccine Brand*	Optum (data through 4/2022)	Carelon Research (data through 4/2022)	CVS Health (data through 2/2022)	CMS (data through 3/2022)
	Overall	1,689,421	2,139,967	1,351,973	6,251,603
	BNT162b2	1,000,053	1,329,255	797,434	3,044,019
Acute Myocardial Infarction	mRNA-1273	660,412	771,677	534,648	3,130,235
	Ad26.COV2.S	24,714	37,638	18,699	77,349
	Overall	1,927,599	2,345,700	1,638,582	6,480,438
Anaphylaxis	BNT162b2	1,140,207	1,455,706	967,037	3,161,023
Anaphylaxis	mRNA-1273	753,975	846,246	647,516	3,238,065
	Ad26.COV2.S	28,577	42,200	22,627	81,350
	Overall	1,688,969	2,139,815	1,351,792	6,294,970
Appendicitis	BNT162b2	999,710	1,329,114	797,320	3,066,139
Appendictus	mRNA-1273	660,294	771,644	534,571	3,150,874
	Ad26.COV2.S	24,726	37,659	18,708	77,957
	Overall	1,858,202	2,322,687	1,519,376	6,449,310
Bell's Palsy	BNT162b2	1,099,406	1,441,734	896,440	3,145,205
Bell's l'alsy	mRNA-1273	726,841	838,198	600,541	3,223,344
	Ad26.COV2.S	27,261	41,243	21,071	80,761
	Overall	1,690,750	2,141,767	1,353,047	6,285,282
Common Site Thrombosis with	BNT162b2	1,000,825	1,330,319	798,052	3,060,858
Thrombocytopenia Syndrome	mRNA-1273	660,943	772,364	535,076	3,146,593
	Ad26.COV2.S	24,738	37,686	18,724	77,831
	Overall	1,684,942	2,134,016	1,348,081	6,195,088
	BNT162b2	997,418	1,325,657	795,204	3,013,969
Deep Vein Thrombosis	mRNA-1273	658,639	769,424	533,046	3,104,233
	Ad26.COV2.S	24,656	37,542	18,643	76,886
	Overall	1,691,142	2,142,258	1,353,408	6,299,613
Disseminated Intravascular	BNT162b2	1,001,048	1,330,623	798,250	3,068,400
Coagulation	mRNA-1273	661,097	772,545	535,229	3,153,195
Cougunation	Ad26.COV2.S	24,752	37,692	18,733	78,018
	Overall	1,859,342	2,324,304	1,520,448	6,459,403
	BNT162b2	1,100,043	1,442,692	897,030	3,150,231
Encephalitis or Encephalomyelitis	mRNA-1273	727,319	838,829	601,003	3,228,290
	Ad26.COV2.S	27,283	41,270	21,090	80,882
	Overall	•			,
	BNT162b2	1,691,168	2,142,321	1,353,443	6,299,987 3,068,597
Guillain-Barré Syndrome		1,001,069	1,330,662	798,277	
	mRNA-1273	661,102	772,566	535,237	3,153,369
	Ad26.COV2.S	24,752	37,695	18,733	78,021
	Overall	1,690,947	2,142,083	1,353,243	6,294,837
Hemorrhagic Stroke	BNT162b2	1,000,939	1,330,523	798,170	3,065,877
	mRNA-1273	661,015	772,470	535,147	3,151,005
	Ad26.COV2.S	24,748	37,692	18,730	77,955
	Overall	1,690,045	2,140,779	1,352,500	6,286,013
Immune Thrombocytopenia	BNT162b2	1,000,389	1,329,681	797,718	3,061,612
minune mioniboeytopenia	mRNA-1273	660,673	772,028	534,867	3,146,522
	Ad26.COV2.S	24,738	37,673	18,720	77,879
	Overall	1,690,317	2,141,214	1,352,672	6,293,962
My conditio (D-miditi-	BNT162b2	1,000,523	1,329,975	797,820	3,065,519
Myocarditis/Pericarditis	mRNA-1273	660,808	772,161	534,939	3,150,486
	Ad26.COV2.S	24,742	37,682	18,718	77,957
Narcolepsy	Overall	1,689,745	2,140,143	1,352,291	6,294,962

Adverse Event	Vaccine Brand*	Optum (data through 4/2022)	Carelon Research (data through 4/2022)	CVS Health (data through 2/2022)	CMS (data through 3/2022)
	BNT162b2	1,000,279	1,329,369	797,646	3,066,033
	mRNA-1273	660,493	771,724	534,728	3,150,965
	Ad26.COV2.S	24,730	37,653	18,721	77,964
	Overall	1,690,389	2,141,279	1,352,772	6,271,813
Non-homowike sie Studie	BNT162b2	1,000,577	1,330,013	797,888	3,053,779
Non-hemorrhagic Stroke	mRNA-1273	660,826	772,195	534,969	3,140,346
	Ad26.COV2.S	24,741	37,674	18,719	77,688
	Overall	1,686,537	2,136,235	1,349,614	6,222,146
Dulmonom, Embolism	BNT162b2	998,322	1,326,934	796,022	3,028,297
Pulmonary Embolism	mRNA-1273	659,274	770,309	533,725	3,116,714
	Ad26.COV2.S	24,703	37,600	18,675	77,135
	Overall	1,691,160	2,142,311	1,353,437	6,299,944
T	BNT162b2	1,117,841	1,330,661	798,274	3,068,584
Transverse Myelitis	mRNA-1273	661,100	772,557	535,234	3,153,341
	Ad26.COV2.S	24,752	37,695	18,733	78,019
	Overall	1,691,155	2,142,284	1,353,417	6,299,696
Unusual Site Thrombosis with	BNT162b2	1,001,068	1,330,637	798,262	3,068,441
Thrombocytopenia Syndrome	mRNA-1273	661,090	772,554	535,226	3,153,238
	Ad26.COV2.S	24,752	37,695	18,733	78,017

*BNT162b2 and mRNA-1273 vaccine doses do not add up to 'Overall' due to vaccination-days with multiple products.

Table 3. Incidence Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 18–64 Years Old Enrolled in Commercial Insurance (Meta-Analyzed across Commercial Databases)

Adverse Events	Vaccine Brand	No. Observed Cases	IRR (95% CI)
	BNT162b2	186	0.82 (0.71 – 0.95)
Acute Myocardial Infarction	mRNA-1273	140	0.97 (0.82 – 1.14)
Annahulauta	BNT162b2	<11	4.92* (2.20 – 10.98)
Anaphylaxis	mRNA-1273	<11	5.70* (1.69 – 19.21)
	BNT162b2	295	0.95 (0.73 – 1.25)
Appendicitis	mRNA-1273	164	0.89 (0.66 - 1.21)
Dell's Deley	BNT162b2	331	0.97 (0.83 – 1.13)
Bell's Palsy	mRNA-1273	173	0.84 (0.62 - 1.13)
Common Site Thrombosis with	BNT162b2	43	0.82 (0.61 - 1.11)
Thrombocytopenia Syndrome	mRNA-1273	25	0.68 (0.23 - 2.04)
	BNT162b2	357	0.76 (0.66 – 0.88)
Deep Vein Thrombosis	mRNA-1273	258	0.87 (0.77 – 0.99)
Disseminated Intravascular	BNT162b2	<11	0.94 (0.49 - 1.80)
Coagulation	mRNA-1273	<11	1.22 (0.54 – 2.78)
	BNT162b2	12	2.28 (0.96 - 5.43)
Encephalitis or Encephalomyelitis	mRNA-1273	<11	1.28 (0.53 – 3.09)
	BNT162b2	<11	0.82 (0.37 – 1.84)
Guillain-Barré Syndrome	mRNA-1273	<11	2.75 (0.76 – 9.95)
	BNT162b2	32	0.92 (0.48 – 1.74)
Hemorrhagic Stroke	mRNA-1273	17	0.85 (0.53 – 1.34)
	BNT162b2	91	1.03 (0.70 – 1.52)
Immune Thrombocytopenia	mRNA-1273	51	0.99 (0.65 – 1.50)
Myocarditis/Pericarditis: All Care	BNT162b2	41	1.95 (1.38 – 2.75)
Settings (18-45 years of age)	mRNA-1273	24	2.19 (1.08 - 4.48)
Myocarditis/Pericarditis: All Care	BNT162b2	38	1.23 (0.90 – 1.68)
Settings (46-64 years of age)	mRNA-1273	34	1.69 (1.21 – 2.35)
Myocarditis/Pericarditis: IP/OP-ED (18-	BNT162b2	15	2.31 (1.19 – 4.51)
45 years of age)	mRNA-1273	11	3.38* (1.51 – 7.58)
Myocarditis/Pericarditis: IP/OP-ED (46-	BNT162b2	<11	1.01 (0.52 – 1.93)
64 years of age)	mRNA-1273	12	2.38 (1.24 – 4.56)
	BNT162b2	96	0.82 (0.59 – 1.13)
Narcolepsy	mRNA-1273	57	0.89 (0.62 – 1.27)
	BNT162b2	97	0.8 (0.55 – 1.17)
Non-hemorrhagic Stroke	mRNA-1273	65	0.82 (0.64 - 1.04)
	BNT162b2	309	1.01 (0.91 – 1.13)
Pulmonary Embolism	mRNA-1273	181	0.97 (0.81 – 1.15)
	BNT162b2	<11	0.98 (0.29 - 3.31)
Transverse Myelitis	mRNA-1273	<11	1.23 (0.36 - 4.14)
Unusual Site Thrombosis with	BNT162b2	<11	0.66 (0.24 – 1.78)
Thrombocytopenia Syndrome	mRNA-1273	<11	0.94 (0.28 - 3.16)

*Indicates the adverse event for the specific vaccine brand has signaled in the analyses. Cell sizes 1-10 were masked for confidentiality.

Care Settings Definition: IP referred to inpatient facility claims. OP-ED referred to a subset of outpatient facility claims occurring in the emergency department. OP/PB referred to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service.

Table 4. Incidence Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 65 Years and Older Enrolled in Medicare

Adverse Events	Vaccine Brand	No. Vaccine Doses	No. Observed Cases	Observed Person- Time (Years)	IRR (95% CI)
	BNT162b2	3,044,019	2,478	214,600	0.89 (0.85 - 0.92)
Acute Myocardial Infarction	mRNA-1273	3,130,235	2,434	216,853	0.9 (0.86 - 0.94)
Anorekularia	BNT162b2	3,161,023	<11	16,338	2.12 (0.44 - 6.20)
Anaphylaxis	mRNA-1273	3,238,065	<11	16,535	0 (0.00 – 2.53)
A man an alt state	BNT162b2	3,066,139	239	318,926	0.95 (0.83 - 1.08)
Appendicitis	mRNA-1273	3,150,874	258	320,221	1.01 (0.89 – 1.14)
Dell's Delay	BNT162b2	3,145,205	803	334,038	1.11* (1.03 – 1.19)
Bell's Palsy	mRNA-1273	3,223,344	722	336,386	1 (0.93 – 1.08)
Common Site Thrombosis with	BNT162b2	3,060,858	737	224,291	0.91 (0.84 - 0.98)
Thrombocytopenia Syndrome	mRNA-1273	3,146,593	708	227,919	0.88 (0.82 - 0.95)
	BNT162b2	3,013,969	2,298	215,607	0.78 (0.75 - 0.81)
Deep Vein Thrombosis	mRNA-1273	3,104,233	2,026	218,817	0.71 (0.68 - 0.74)
	BNT162b2	3,068,400	63	208,306	0.83 (0.64 - 1.06)
Disseminated Intravascular Coagulation	mRNA-1273	3,153,195	53	208,026	0.72 (0.54 - 0.95)
Francisco de la constalitio	BNT162b2	3,150,231	38	316,355	1.37 (0.97 – 1.89)
Encephalomyelitis	mRNA-1273	3,228,290	33	312,678	1.23 (0.85 – 1.73)
Cutillatin Denné Cundurana	BNT162b2	3,068,597	12	311,896	0.86 (0.45 - 1.51)
Guillain-Barré Syndrome	mRNA-1273	3,153,369	<11	310,292	0.72 (0.34 - 1.32)
Llomorrhagia Stroka	BNT162b2	3,065,877	393	213,982	0.87 (0.79 - 0.96)
Hemorrhagic Stroke	mRNA-1273	3,151,005	370	215,414	0.85 (0.76 - 0.94)
Immune Thrombocytopenia	BNT162b2	3,061,612	333	328,185	1.11 (0.99 – 1.24)
	mRNA-1273	3,146,522	322	332,293	1.07 (0.96 – 1.20)
Muccorditic (Dericorditic	BNT162b2	3,065,519	161	165,642	1.09 (0.93 – 1.27)
Myocarditis/Pericarditis	mRNA-1273	3,150,486	144	167,882	0.98 (0.82 - 1.15)
Narcology	BNT162b2	3,066,033	135	324,439	1.12 (0.94 – 1.32)
Narcolepsy	mRNA-1273	3,150,965	93	327,554	0.77 (0.62 - 0.94)
Non-hemorrhagic Stroke	BNT162b2	3,053,779	1,427	214,901	0.76 (0.72 – 0.80)
Non-nemormagic scroke	mRNA-1273	3,140,346	1,389	217,119	0.77 (0.73 – 0.81)
Pulmonary Embolism	BNT162b2	3,028,297	1,749	217,775	1.05* (1.001 - 1.100)
	mRNA-1273	3,116,714	1,649	221,084	1 (0.95 – 1.05)
Transverse Myelitis	BNT162b2	3,068,584	17	317,121	1.57 (0.92 – 2.52)
	mRNA-1273	3,153,341	<11	317,588	0.56 (0.21 – 1.23)
Unusual Site Thrombosis with	BNT162b2	3,068,441	28	223,602	1.27 (0.84 - 1.83)
Thrombocytopenia Syndrome	mRNA-1273	3,153,238	20	226,866	0.88 (0.54 - 1.36)

*Indicates the adverse event for the specific vaccine brand has signaled in the analyses.

Medicare database contains data through March 2022.

Cell sizes 1-10 were masked for confidentiality.

Supplemental Table 1. Description of Characteristics of Administrative Claims Data Sources Used in the Study

Data Sou	Data Source		Claims Data Lag	Enrollees
Centers for Medicare & Medicaid Services (CMS) administrative claims data source	Medicare Fee-For- Service	Weekly	Approximately 80% data completeness in 1-3 months for inpatient, outpatient, and professional claims	~48 million totals from 2017-2021 ~33 million annually
	CVS Health	Monthly	Approximately 80% data completeness in 3-4 months for inpatient claims, 2-3 months for outpatient claims, and 1-2 months for	~37 million total from 2018- 2021 ~22 million annually
Commercial claims data	Optum Pre- Adjudicate d Claims	Bi-Weekly	Approximately 80% data completeness in 1-2 months for inpatient, outpatient, and professional claims	~29 million total from 2017- 2021 ~15-16 million annually
sources	Carelon Research	Monthly	Approximately 80% data completeness in 2-3 months for inpatient claims and 1-2 months for outpatient and professional claims	~46 million total from 2016- 2021 ~24 million annually

Supplemental Table 2. COVID-19 Vaccine Emergency Use Authorization (EUA) Dates
and Dose Schedule Recommendations

Manufacturer	Name	Vaccine Authorizatio	n Dates ¹		Dosing Interval ^{2,7,29,30,53}
	BNT162b2	1 st Dose	12/11/2020	-	21 days between doses 1, 2
	BNT162b2-	2 nd Dose	12/11/2020	-	28 days between doses 2, 3
Pfizer-	BioNTech	3 rd Dose	8/12/2021	-	5 months between primary series and booster
BioNTech	COVID-19	1 st Monovalent Booster	9/22/2021		dose
	Vaccine	2 nd Monovalent Booster	3/29/2022	-	4 months between first and second booster
		Bivalent Booster Dose	8/31/2022		doses
	mRNA-1273	1 st Dose	12/18/2020	-	28 days between doses 1, 2
		2 nd Dose	12/18/2020	-	28 days between doses 2, 3
Moderna		3 rd Dose	8/12/2021	-	5 months between primary series and booster
MOUEITIA	COVID-19 Vaccine	1 st Monovalent Booster	10/20/2021		dose
	vaccine	2 nd Monovalent Booster	3/29/2022	-	4 months between first and second booster
		Bivalent Booster Dose	8/31/2022		doses
Janssen	Ad26.COV2.S	1 st Dose	2/27/2021	-	2 months between primary series and booster
Janssen	COVID-19	Monovalent Booster	10/20/2022		dose

Supplemental Table 3. Number of Third COVID-19 mRNA Vaccine Doses Included in Adverse Event Specific Analyses

	No. Third Vaccine Doses										
Adverse Events	Opt	tum	Carelon	Research	CVS H	Iealth	CM	1S			
	BNT162b2	mRNA- 1273	BNT162b2	mRNA- 1273	BNT162b2	mRNA- 1273	BNT162b2	mRNA- 1273			
Total No. Doses	1,280,591	845,142	1,458,076	847,366	1,064,775	707,993	3,336,862	3,399,048			
	Total No. Doses Satisfying Criteria*										
Acute Myocardial Infarction	927,568	547,891	1,092,311	621,495	730,364	424,230	3,044,019	3,130,235			
Anaphylaxis	1,056,780	624,702	1,196,966	679,812	884,991	512,462	3,161,023	3,238,065			
Appendicitis	927,255	547,821	1,092,238	621,550	730,282	424,237	3,066,139	3,150,874			
Bell's Palsy	1,019,227	602,273	1,186,633	673,853	821,224	476,422	3,145,205	3,223,344			
Common Site Thrombosis with Thrombocytopenia Syndrome	928,298	548,354	1,093,202	622,103	730,940	424,599	3,060,858	3,146,593			
Deep Vein Thrombosis	925,149	546,338	1,089,291	619,631	728,300	422,902	3,013,969	3,104,233			
Disseminated Intravascular Coagulation	928,501	548,491	1,093,456	622,250	731,126	424,728	3,068,400	3,153,195			
Encephalitis or Encephalomyelitis	1,019,811	602,672	1,187,445	674,369	821,778	476,788	3,150,231	3,228,290			
Guillain-Barré Syndrome	928,522	548,498	1,093,491	622,268	731,152	424,733	3,068,597	3,153,369			
Hemorrhagic Stroke	928,411	548,417	1,093,370	622,183	731,047	424,657	3,065,877	3,151,005			
Immune Thrombocytopenia	927,897	548,125	1,092,660	621,808	730,622	424,419	3,061,612	3,146,522			
Myocarditis/Pericarditis: All Care Settings	928,015	548,249	1,092,916	621,947	730,731	424,495	3,065,519	3,150,486			
Myocarditis/Pericarditis: IP/OP-ED Settings**	928,446	548,454	1,093,371	622,206	731,084	424,704	NA	NA			
Narcolepsy	927,790	547,981	1,092,465	621,591	730,583	424,352	3,066,033	3,150,965			
Non-hemorrhagic Stroke	928,079	548,247	1,092,941	621,961	730,797	424,504	3,053,779	3,140,346			
Pulmonary Embolism	925,962	546,894	1,090,407	620,352	729,067	423,457	3,028,297	3,116,714			
Transverse Myelitis	928,516	548,495	1,093,491	622,259	731,148	424,731	3,068,584	3,153,341			
Unusual Site Thrombosis with Thrombocytopenia Syndrome	928,520	548,486	1,093,471	622,254	731,136	424,726	3,068,441	3,153,238			

*Total numbers of mRNA vaccine doses administered by brand that satisfied analysis inclusion criteria for each adverse event.

**Analyses for myocarditis/pericarditis stratified by care setting were not conducted in the Medicare database. NA means not applicable.

Care Settings Definition: IP referred to inpatient facility claims. OP-ED referred to a subset of outpatient facility claims occurring in the emergency department. OP/PB referred to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service.

Supplemental Table 4. Incidence Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 18-64 Years Old Enrolled in Commercial Insurance Databases, Stratified by Prior COVID-19 Diagnosis, Meta-Analyzed for Commercial Claims Databases

Adverse Events	Vaccine	With Prior CO	VID-19 Diagnosis	Without Prior COVID-19 Diagnosis		
	Brand	No. Observed Cases	IRR (95% CI)	No. Observed Cases	IRR (95% CI)	
	BNT162b2	22	1.32 (0.88–1.99)	164	0.79 (0.68 – 0.92)	
Acute Myocardial Infarction	mRNA-1273	13	1.35 (0.70 – 2.57)	127	0.95 (0.80 – 1.13)	
Ananhulauia	BNT162b2	<11	37.26* (6.69 – 207.58)	<11	6.21* (2.50 – 15.39)	
Anaphylaxis	mRNA-1273	0	NA	<11	6.15* (1.82 – 20.71)	
A second state	BNT162b2	29	1.22 (0.86 – 1.75)	266	0.93 (0.71 – 1.23)	
Appendicitis	mRNA-1273	17	1.12 (0.28 – 4.46)	147	0.87 (0.68 – 1.10)	
Dell's Deless	BNT162b2	38	1.42 (0.83 – 2.45)	293	0.93 (0.77 – 1.12)	
Bell's Palsy	mRNA-1273	17	0.95 (0.26 – 3.49)	156	0.82 (0.64 – 1.04)	
Common Site Thrombosis with	BNT162b2	<11	1.01 (0.42 – 2.44)	39	0.81 (0.60 - 1.11)	
Thrombocytopenia Syndrome	mRNA-1273	<11	5.83* (2.28 – 14.92)	21	0.66 (0.27 – 1.65)	
	BNT162b2	46	1.27 (0.90 – 1.77)	311	0.72 (0.63 – 0.81)	
Deep Vein Thrombosis	mRNA-1273	32	1.54 (0.96 – 2.47)	226	0.83 (0.73 – 0.94)	
Disseminated Intravascular	BNT162b2	<11	4.26 (0.76 – 23.74)	<11	0.95 (0.48 – 1.91)	
Coagulation	mRNA-1273	0	NA	<11	1.31 (0.58 – 2.99)	
	BNT162b2	<11	26.85* (7.43 – 96.99)	<11	1.98 (1.10 – 3.58)	
Encephalitis or Encephalomyelitis	mRNA-1273	0	NA	<11	1.37 (0.57 – 3.31)	
	BNT162b2	<11	4.91 (0.88 – 27.35)	<11	0.76 (0.32 – 1.84)	
Guillain-Barré Syndrome	mRNA-1273	<11	18.19* (3.26 – 101.35)	<11	1.49 (0.27 – 8.30)	
	BNT162b2	<11	1.7 (0.61 – 4.76)	29	0.93 (0.54 – 1.62)	
Hemorrhagic Stroke	mRNA-1273	<11	2.22 (0.66 – 7.48)	15	0.8 (0.49 – 1.30)	
	BNT162b2	<11	1.14 (0.56 – 2.31)	84	1.03 (0.72 – 1.48)	
Immune Thrombocytopenia	mRNA-1273	<11	1.24 (0.44 – 3.46)	48	1.01 (0.68 – 1.51)	
Myocarditis/Pericarditis: All Care	BNT162b2	<11	2.65 (0.95 – 7.41)	38	1.96 (1.32 – 2.93)	
Settings (18-45 years of age)	mRNA-1273	<11	7.22* (2.58 – 20.19)	21	2.09 (1.16 – 3.77)	
Myocarditis/Pericarditis: All Care	BNT162b2	<11	1.22 (0.45 – 3.28)	35	1.23 (0.89 – 1.71)	
Settings (46-64 years of age)	mRNA-1273	<11	6.61* (3.26 - 13.41)	27	1.45 (1.00 – 2.10)	
Myocarditis/Pericarditis: IP/OP-ED	BNT162b2	0	NA	15	2.5 (1.28 – 4.85)	
(18-45 years of age)	mRNA-1273	0	NA	<11	3.63* (1.62 – 8.15)	
Myocarditis/Pericarditis: IP/OP-ED	BNT162b2	<11	4.66 (0.84 – 25.98)	<11	1.02 (0.51 – 2.04)	
(46-64 years of age)	mRNA-1273	<11	11.35* (4.06 – 31.74)	<11	2.03 (1.09 – 3.77)	
	BNT162b2	12	1.12 (0.39 – 3.23)	84	0.8 (0.63 - 1.02)	
Narcolepsy	mRNA-1273	<11	1.05 (0.47 – 2.34)	52	0.88 (0.59 - 1.31)	
	BNT162b2	<11	0.53 (0.24 – 1.18)	92	0.82 (0.55 – 1.24)	
Non-hemorrhagic Stroke	mRNA-1273	<11	1.69 (0.91 – 3.13)	56	0.77 (0.59 – 0.99)	
	BNT162b2	28	1.08 (0.51 – 2.28)	281	1 (0.89 – 1.13)	
Pulmonary Embolism	mRNA-1273	14	1.06 (0.64 – 1.77)	167	0.97 (0.78 – 1.20)	
-	BNT162b2	0	NA	<11	1.06 (0.32 – 3.59)	
Transverse Myelitis	mRNA-1273	0	NA	<11	1.32 (0.39 – 4.44)	
Unusual Site Thrombosis with	BNT162b2	<11	8.43* (1.51 – 46.96)	<11	0.73 (0.22 – 2.47)	
Thrombocytopenia Syndrome	mRNA-1273	0	NA	<11	1.01 (0.30 – 3.39)	

*Indicates the adverse event for the specific vaccine brand has signaled in the analyses.

Cells with 'NA' indicate adverse events for which an IRR (95% CI) could not be estimated due to zero observed cases. Cell sizes 1-10 were masked for confidentiality.

Supplemental Table 5. Incident Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 65 Years and Older Enrolled in Medicare, Stratified by Prior COVID-19 Diagnosis

Adverse Events	Vaccine Brand	With Prior COVID-19 Diagnosis			Without Prior COVID-19 Diagnosis		
		No. Observed Cases	Observed Person-Time (Years)	IRR (95% CI)	No. Observed Cases	Observed Person-Time (Years)	IRR (95% CI)
Acute Myocardial Infarction	BNT162b2	274	14,705	1.15* (1.02 – 1.29)	2204	199,895	0.86 (0.83 – 0.90)
	mRNA-1273	216	11,396	1.33* (1.16 – 1.52)	2,218	205,457	0.87 (0.84 – 0.91)
Anaphylaxis	BNT162b2	0	1,140	0 (0.00 – 41.98)	<11	15,198	2.26 (0.47 – 6.61)
	mRNA-1273	0	888	0 (0.00 – 49.92)	0	15,647	0 (0.00 – 2.66)
Appendicitis	BNT162b2	21	21,878	1.31 (0.81 – 2.01)	218	297,048	0.93 (0.81 – 1.06)
	mRNA-1273	<11	16,796	0.85 (0.42 – 1.52)	247	303,425	1.02 (0.89 – 1.15)
Bell's Palsy	BNT162b2	60	22,881	1.14 (0.87 – 1.47)	743	311,158	1.11* (1.03 – 1.19)
	mRNA-1273	48	17,662	1.23 (0.91 – 1.63)	674	318,725	0.99 (0.91 – 1.06)
Common Site Thrombosis with	BNT162b2	83	15,514	1.23 (0.98 – 1.52)	654	208,777	0.88 (0.81 – 0.95)
Thrombocytopenia Syndrome	mRNA-1273	57	12,076	1.19 (0.90 – 1.54)	651	215,843	0.86 (0.80 - 0.93)
Deep Vein Thrombosis	BNT162b2	261	14,696	1 (0.88 – 1.13)	2,037	200,912	0.76 (0.73 – 0.79)
	mRNA-1273	166	11,516	0.94 (0.80 – 1.09)	1,860	207,301	0.7 (0.66 – 0.73)
Disseminated Intravascular	BNT162b2	0	14,267	0 (0.00 – 0.54)	63	194,039	0.91 (0.70 – 1.16)
Coagulation	mRNA-1273	<11	10,888	1.53 (0.61 – 3.15)	46	197,137	0.67 (0.49 – 0.89)
Encephalitis or Encephalomyelitis	BNT162b2	<11	21,208	1.33 (0.27 – 3.88)	35	295,147	1.38 (0.96 – 1.92)
	mRNA-1273	<11	15,949	1.3 (0.16 – 4.68)	31	296,728	1.23 (0.83 – 1.74)
Guillain-Barré Syndrome	BNT162b2	0	21,093	0 (0.00 – 4.22)	12	290,803	0.92 (0.48 – 1.61)
	mRNA-1273	0	15,939	0 (0.00 – 5.36)	<11	294,353	0.75 (0.36 – 1.39)
Hemorrhagic Stroke	BNT162b2	40	14,759	1.06 (0.76 – 1.45)	353	199,223	0.85 (0.77 – 0.95)
	mRNA-1273	26	11,382	1 (0.65 – 1.47)	344	204,032	0.84 (0.75 – 0.93)
Immune Thrombocytopenia	BNT162b2	37	22,705	1.66* (1.17 – 2.29)	296	305,480	1.07 (0.95 – 1.20)
	mRNA-1273	17	17,624	1.02 (0.59 – 1.63)	305	314,669	1.08 (0.96 – 1.20)
Myocarditis/Pericarditis	BNT162b2	22	11,554	1.89* (1.18 – 2.86)	139	154,087	1.02 (0.86 – 1.21)
	mRNA-1273	13	9,000	1.53 (0.81 – 2.62)	131	158,882	0.94 (0.79 – 1.12)
Narcolepsy	BNT162b2	12	22,422	1.26 (0.65 – 2.19)	123	302,017	1.1 (0.92 – 1.32)
	mRNA-1273	<11	17,356	0.72 (0.23 – 1.68)	88	310,198	0.77 (0.62 – 0.95)
Non-hemorrhagic Stroke	BNT162b2	158	14,825	1 (0.85 – 1.17)	1,269	200,076	0.74 (0.70 – 0.78)
	mRNA-1273	101	11,486	0.93 (0.76 – 1.13)	1,288	205,633	0.76 (0.72 – 0.80)
Pulmonary Embolism	BNT162b2	182	14,951	1.36* (1.17 – 1.58)	1,567	202,824	1.02 (0.97 – 1.07)
	mRNA-1273	137	11,671	1.43* (1.20 – 1.69)	1,512	209,413	0.98 (0.93 – 1.03)
Transverse Myelitis	BNT162b2	<11	21,625	2.21 (0.27 – 7.99)	15	295,496	1.51 (0.85 – 2.50)
	mRNA-1273	<11	16,502	3.19 (0.39 – 11.53)	<11	301,087	0.4 (0.11 – 1.02)
Unusual Site Thrombosis with	BNT162b2	<11	15,472	2.63 (0.72 – 6.74)	24	208,130	1.17 (0.75 – 1.73)
Thrombocytopenia Syndrome	mRNA-1273	<11	11,997	0.83 (0.02 – 4.65)	19	214,869	0.88 (0.53 – 1.38)

*Indicates the adverse event for the specific vaccine brand has signaled in the analyses.

Medicare database contains data through March 2022.

Cell sizes 1-10 were masked for confidentiality.

Supplemental Table 6. Number of COVID-19 Homologous and Heterologous Third Vaccine Doses Administered Following Primary Series

	Optum	Carelon Research	CVS Health	CMS	
Vaccine Brand	No. Vaccinees (%)	No. Vaccinees (%)	No. Vaccinees (%)	No. Vaccinees (%)	
Primary Series: BNT162b2	1,182,306	1,326,121	1,023,199	5,208,339	
Total third vaccine doses among BNT162b2 primary series recipients	1,182,306 (100.00)	1,326,121 (100.00)	1,023,199 (100.00)	3,243,792 (100.00)	
Ad26.COV2.S booster doses				3,301 (0.10)	
BNT162b2 third vaccine doses	1,062,247 (89.85)	1,198,742 (90.39)	903,546 (88.31)	3,136,719 (96.70)	
mRNA-1273 third vaccine doses	120,059 (10.15)	127,379 (9.61)	119,653 (11.69)	103,772 (3.20)	
Primary Series: mRNA-1273	700,210	768,750	585,837	5,233,843	
Total third vaccine doses among mRNA-1273 primary series recipients	700,210 (100.00)	768,750 (100.00)	585,837 (100.00)	3,370,141 (100.00)	
Ad26.COV2.S booster doses				6,259 (0.19)	
BNT162b2 third vaccine doses	72,499 (10.35)	88,046 (11.45)	62,976 (10.75)	149,253 (4.43)	
mRNA-1273 third vaccine doses	627,711 (89.65)	680,704 (88.55)	522,861 (89.25)	3,214,629 (95.39)	
Primary Series: Ad26.COV2.S	37,610	42,855	26,700	541,723	
Total third vaccine doses among Ad26.COV2.S primary series recipients	37,610 (100.00)	42,855 (100.00)	26,700 (100.00)	211,684 (100.00)	
Ad26.COV2.S booster doses	25,480 (67.75)	35,565 (82.99)	21,411 (80.19)	80,147 (37.86)	
BNT162b2 third vaccine doses	6,318 (16.80)	3,715 (8.67)	2,340 (8.76)	50,890 (24.04)	
mRNA-1273 third vaccine doses	5,812 (15.45)	3,575 (8.34)	2,949 (11.04)	80,647 (38.10)	

Conflicts of Interest

All authors have no conflicts of interest to disclose.

Ethics Statement

As a public health surveillance activity, this study was not subject to requirements for Institutional Review Board review.

Authorship Contributions

All authors contributed to the concept and design of the study and interpretation of the data. A. Shoaibi drafted the manuscript and all authors reviewed it. K. Matuska, H. Lyu, R. McEvoy, Z. Wan, M. Hu, D. Beachler, A. Secora, N. Selvam, D. Djibo, C. McMahill-Walraven, J. Seeger, K. Amend, J. Song, R. Clifford, R. Forshee, and S. Anderson acquired and managed the data and performed analyses. The views expressed here are those of the authors and not necessarily those of the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Department of Health and Human Services, CVS Health/Aetna, Carelon Research, IQVIA, or Optum Epidemiology. This work has not been presented publicly, previously published, or is under current consideration by another journal.

Funding

There were no extra-institutional sources of funding.

Acknowledgments

We would like to thank Gyanada Acharya, Derick Ambarsoomzadeh, Mahasweta Mitra, Michelle Ondari, Ellie Smith, and Zoe Wu from Acumen LLC; Shiva Vojjala, Ramya Avula, Shiva Chaudhary, Qian Si, Dianna Hayden, Shanthi P Sagare, Ramin Riahi, Brian Greenwald, and Grace Stockbower from Carelon Research; Michael Goodman, Michael Bruhn, and Ruth Weed from IQVIA; Anne Marie Kline, Nancy B. Shaik, Ana M. Martinez-Baquero, Smita Bhatia, Carla Brannan, Vaibhav Sharma, Eugenio Abente, and Jonathan Deshazo from CVS Health; and Grace Yang, Sarah Sargen, Alexandra Stone, Wafa Tarazi, Megan Ketchell, Kathryn Federici, Amaka Ume, Emily Myers, Eli Wolter, Jackson Slaney, Bobby Smith, Lauren Peetluk, and Elizabeth Bell from Optum for their assistance with data validation, analysis, manuscript preparation, and project coordination.

References

- 1. FDA C. COVID-19 Vaccines. *Coronavirus Disease 2019 (COVID-19)* 2022; https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019covid-19/covid-19-vaccines?msclkid=2b8a54e5b49e11ecb160a21c546d50fa. Accessed 04/04/2022, 2022.
- 2. Administration USFaD. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers); Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coranvirus Disease 2019 (COVID-19). In. FDA Media 2022.
- 3. Wong H-L, Tworkoski E, Zhou CK, et al. Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older. *SSRN*. 2022.
- 4. Lloyd P, Hu M, Wong H-L, et al. Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years. *Vaccine*. 2022.
- 5. Cirillo N, Doan R. The association between COVID-19 vaccination and Bell's Palsy. *The Lancet Infectious Diseases*. 2022;22(1):5-6.
- 6. Prevention CfDCa. Immunization Information Systems (IIS). 2019.
- Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals [press release]. U.S. FDA Press Announcements August 12, 2021 2021.
- 8. Administration USFaD. Safety Assessment of 3rd Dose/Booster Dose of COVID-19 mRNA Vaccines: Master Protocol. 2022.
- 9. Greene SK, Kulldorff M, Yin R, et al. Near real-time vaccine safety surveillance with partially accrued data. *Pharmacoepidemiology and drug safety*. 2011;20(6):583-590.
- 10. EMA E. Signal assessment report on myocarditis and pericarditis with Spikevax -COVID-19 mRNA vaccine (nucleosidemodified). In: Committee PRA, ed. European Medicines Authority Science Medicines Health2021.
- 11. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med.* 2021;385(23):2140-2149.
- 12. PHO. Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to April 3, 2022 In: Ontario PH, ed. Media Documents2022.
- 13. Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *JAMA*. 2022;327(4):331-340.
- 14. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. *Jama*. 2021;326(12):1210-1212.
- 15. Kim HW, Jenista ER, Wendell DC, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol.* 2021;6(10):1196-1201.
- 16. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics*. 2021;148(3).
- Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol*. 2021;6(10):1202-1206.
- 18. Rosner CM, Genovese L, Tehrani BN, et al. Myocarditis Temporally Associated With COVID-19 Vaccination. *Circulation*. 2021;144(6):502-505.

- 19. Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. *Bmj.* 2021;375:e068665.
- 20. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med.* 2022;28(2):410-422.
- 21. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *N Engl J Med.* 2021;385(23):2132-2139.
- 22. Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Announcement [press release]. Vaccine Adisory Committee Meeting Calendar, October 14-15 2021 2021.
- 23. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine*. 2002;21(11):1539-1558.
- 24. Shoaibi A, Lloyd PC, Wong H-L, et al. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S. *Vaccine*. 2023;41(32):4666-4678.
- 25. Burn E, Li X, Delmestri A. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis. *medRxiv*. 2021.
- 26. Ho FK, Man KKC, Toshner M, et al. Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients: A Self-Controlled Case Series Analysis of a Nationwide Cohort. *Mayo Clinic Proceedings*. 2021;96(10).
- 27. Barda N, Dagan N, Ben-Shlomo Y. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med.* 2021.
- Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals [press release].
 FDA News Release, March 29, 2022 2022.
- 29. CDC Recommends Pfizer Booster at 5 months, Additional Primary Dose for Certain Immunocompromised Children [press release]. CDC Newsroom January 4, 2022 2022.
- 30. Administration USFaD. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. 2022.
- Al Qudah Z, Abukwaik W, Souayah N. Stroke after Vaccination in United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. [1990–2010] (P01.009). *Neurology*. 2012;78(1 Supplement):P01.009-P001.009.
- 32. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine*. 2004;351(25):2611-2618.
- 33. Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5675-5684.
- 34. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. *Journal of Allergy and Clinical Immunology*. 2019;143(4):1465-1473.
- 35. Donahue JG, Kieke BA, Lewis EM, et al. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. *Pediatrics*. 2019;144(6):e20191808.

- 36. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. *Vaccine*. 2011;29(46):8279-8284.
- 37. Loucie Renoud eA. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med.* 2021;384(1):20-30.
- 38. Pishko AM, Bussel JB, Cines DB. COVID-19 vaccination and immune thrombocytopenia. *Nat Med.* 2021;27(7):1145-1146.
- 39. Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003;107(23_suppl_1):I-22-I-30.
- 40. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. *Blood.* 2014;123(12):1794-1801.
- 41. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis Haemostasis*. 2020;18(4):844-847.
- 42. Pellegrino P, Carnovale C, Perrone V, et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. *PloS one*. 2013;8(10):e77766.
- 43. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. *American Journal of Epidemiology*. 1979;110(2):105-123.
- 44. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine*. 2013;31(40):4448-4458.
- 45. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. *British Journal of Clinical Pharmacology*. 2003;55(1):107-111.
- 46. D'alò GL, Zorzoli E, Capanna A, et al. Frequently asked questions on seven rare adverse events following immunization. *Journal of Preventive Medicine Hygiene*. 2017;58(1):E13.
- 47. Klein NP. Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and "Head-to-Head" Product Comparisons. Paper presented at: ACIP Meetings; October 21, 2021, 2021.
- 48. Duffy J, Weintraub E, Vellozzi C, DeStefano F. Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United States. *Neurology*. 2014;83(20):1823-1830.
- 49. Montplaisir J, Petit D, Quinn M-J, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. *PloS one*. 2014;9(9):e108489.
- 50. Sarkanen TO, Alakuijala AP, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. *Sleep Medicine Reviews*. 2018;38:177-186.
- 51. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. *Lupus*. 2009;18(13):1198-1204.
- 52. Whitworth HeA. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. *Blood.* 2021;138(2):190-198.
- 53. Administration USFaD. Vaccine Information Fact Sheet for Recipients and Caregivers About Spikevax (COVID-19) Vaccine, mRNA) and the Moderna COVID-19 Vaccine to

Prevent Coronavirus Disease: 2019 (COVID-19) in Individuals 18 Years of Age and Older. In. FDA Media 2022.